Hyderabad-based drug major Aurobindo Pharma Limited has reported a 19.7 percent jump in net profit at Rs 712.2 crore for the quarter ended December 2018 on the back of robust revenue growth in the US and other markets.
Revenues from operations increased 21.5 percent to 5,269.7 crore during the quarter under review as compared to Rs 4336.1 crore in the year ago period.
Giving a boost to the company's performance, the US formulations sales grew by 27.4 percent at Rs 2,433.2, constituting 46 percent of the overall revenues, from Rs 1,909.6 crore in the corresponding previous quarter. The formulations sales for the
